Genetic Sequencing Study of Early Gastric Cancer and Precancerous Gastric Adenoma for Personalized Treatment

What this Trial Is About

Researchers are studying early gastric cancer and precancerous gastric adenoma to improve diagnosis and predict recurrence. These conditions have a high cure rate when detected early, often treatable by endoscopic removal, which helps maintain a good quality of life. However, there are currently no markers available to diagnose early gastric cancer or predict its return after treatment. The study collects tumor tissue and blood samples from patients diagnosed with early gastric cancer or gastric adenoma at different times initially, 2 months, 1 year after treatment, and if recurrence occurs. Advanced genetic testing methods, including targeted sequencing and copy number variation analysis, are used to profile tumors. Additional tests include immunohistochemistry and cancer-specific scans to analyze molecular changes. Participants will undergo sample collection and molecular profiling over up to 2 years to identify biomarkers that help diagnose and predict cancer recurrence. Researchers will review genetic changes over time and measure disease-free survival. The goal is to gather detailed molecular information to support personalized care for these patients.

Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients